Showing 7061-7070 of 8649 results for "".
- Heidelberg Engineering Receives FDA Clearance for Spectralis Flex Module for Supine Imaginghttps://modernod.com/news/heidelberg-engineering-receives-fda-clearance-for-spectralis-flex-module-for-supine-imaging/2482486/Heidelberg Engineering has received FDA clearance for its Spectralis Flex Module, a multimodal diagnostic imaging platform. The new module is designed specifically for imaging the posterior segment of both pediatric and adult patients in a supine position, addressing a need for patients unab
- Ophthalmic Drug Delivery Summit to Convene in San Franciscohttps://modernod.com/news/ophthalmic-drug-delivery-summit-to-convene-in-san-francisco/2482481/In January, over 60 world-leading specialists in ophthalmic drug delivery will gather in San Francisco for the 3rd annual Ophthalmic Drug Delivery Summit, an industry-focused event dedicated to enhancing the effectiveness, durability, and minimally invasive nature of retinal drug delivery.</
- Nanoscope Therapeutics Plans to Submit BLA for Gene Therapy to Treat RPhttps://modernod.com/news/nanoscope-therapeutics-plans-to-submit-bla-for-gene-therapy-to-treat-retinitis-pigmentosa/2482476/Nanoscope Therapeutics has announced a successful meeting with the FDA regarding its lead clinical program, MCO-010, for the treatment of retinitis pigmentosa (RP). Following regulatory feedback from the FDA, the company plans to initiate a rolling submission of its biologics license ap
- Cure Blindness Project Unveils Global Expansion Plan on World Sight Dayhttps://modernod.com/news/cure-blindness-project-unveils-global-expansion-plan-on-world-sight-day/2482471/In honor of World Sight Day on October 10, the non-profit Cure Blindness Project announced an expansion plan that will extend its sight-restoring services to six new countries: Burundi, Democratic Republic of the Congo, Liberia, Pakistan, Paraguay, and Zambia. This move marks the organi
- Ocuphire Publishes Phase 3 Trial Results of Ryzumvi for Reversal of Pharmacologically-Induced Mydriasishttps://modernod.com/news/ocuphire-publishes-phase-3-trial-results-of-ryzumvi-for-pharmacologically-induced-mydriasis-1/2482463/Ocuphire Pharma announced the full results from two pivotal phase 3 clinical trials (MIRA-2 and MIRA-3) that evaluated the safety and efficacy of Ryzumvi (phentolamine ophthalmic solution 0.75%) for reversing pharmacologically-induced mydriasis. The data were
- Hoya Highlights the Impact Rural vs Urban Living Environments May Have On Myopia In Young Childrenhttps://modernod.com/news/hoya-highlights-the-impact-rural-vs-urban-living-environments-may-have-on-myopia-in-young-children/2482457/Hoya Vision Care announced the results of a 5-year epidemiological study conducted in Scotland exploring the correlations between myopia, socio-economic deprivation, and urban or rural dwellings in young children. The study, which reviewed refractive error data from eye examinations in
- Nicox and Glaukos Sign Global Licensing Deal for Glaucoma Drug Candidatehttps://modernod.com/news/nicox-and-glaukos-sign-global-licensing-deal-for-glaucoma-drug-candidate/2482451/Nicox has entered into an exclusive research and license option agreement with Glaukos for NCX 1728, Nicox’s novel nitric oxide (NO)-donating phosphodiesterase-5 (PDE5) inhibitor. The collaboration aims to accelerate research and development efforts for glaucoma and other serious ophth
- Visionix USA Introduces Topography Module for Optovue Solix OCT Systemshttps://modernod.com/news/visionix-usa-introduces-groundbreaking-topography-module-for-optovue-solix-oct-systems/2482448/Visionix USA announced the introduction of its new Topography Module for the Optovue Solix FullRange and Solix Essential OCT/OCT-A systems. This feature integrates topography with OCT and OCT-A, making the Optovue Solix systems a multimodal solution for comprehensive eye assessments.
- Scientists at Medical College of Georgia Explore New Treatment Target for Diabetic Retinopathyhttps://modernod.com/news/scientists-at-medical-college-of-georgia-explore-new-treatment-target-for-diabetic-retinopathy/2482442/Researchers at the Medical College of Georgia at Augusta University are on a mission to find a new treatment target for diabetic retinopathy. With a $1.5 million grant from the National Eye Institute, vascular and endothelial biologist Shruti Sharma, PhD, and a team from the MCG C
- Nanoscope Plans Phase 3 Trial of MCO-010 to Treat Stargardt Macular Degenerationhttps://modernod.com/news/nanoscope-plans-phase-3-trial-of-mco-010-to-treat-stargardt-macular-degeneration/2482440/Nanoscope Therapeutics announced the completion of an End-of-phase 2 (EOP2) meeting with the FDA for its clinical program evaluating MCO-010 for the treatment of severe vision loss caused by Stargardt macular degeneration (SMD), supporting advancement of MCO-010 to a phase 3 registrational trial.